Belite Bio Says UK's MHRA Agrees To Conditional Marketing Authorization For Treatment Of Stargardt Disease With Tinlarebant
Reuters
Nov 20
Nov 2 (Reuters) - Belite Bio Inc :: *BELITE BIO ANNOUNCES UK’S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY AGREES TO CONDITIONAL MARKETING AUTHORIZATION APPLICATION BASED ON INTERIM ANALYSIS RESULTS FOR THE TREATMENT OF STARGARDT DISEASE WITH TINLAREBANT
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.